Evidence map›Paper›PMID 41208993›Full record

Trial reportFrontiers in immunology2025

Xuan Li, Zhidong Han, Kaihong Wu, Bingchai Lin, Saman Azeem, Yiru Jiang, Yao Dong, Zhonghui Gai, Shuguang Fang, Ying Wu and 1 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06680102 (The Effectiveness of Weizmannia Coagulans BC99 in Alleviating Allergic Rhinitis in Adults and Its Impact on the Gut Microbiota.), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06680102 nacompletednot on this map

The Effectiveness of Weizmannia Coagulans BC99 in Alleviating Allergic Rhinitis in Adults and Its Impact on the Gut Microbiota.

TypeinterventionalSponsorWecare Probiotics Co., Ltd.Ran2024 to 2025Enrolled78ConditionsAllergic RhinitisArmsProbiotic, Maltodextrin
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xuan LiCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang, China.
Zhidong HanCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang, China.
Kaihong WuGuangdong Yi Chao Biological Technology Co., Ltd., Shantou, China.
Bingchai LinGuangdong Yi Chao Biological Technology Co., Ltd., Shantou, China.
Saman AzeemCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang, China.
Yiru JiangCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang, China.
Yao DongDepartment of Research and Development, Wecare Probiotics Co., Ltd., Suzhou, China.
Zhonghui GaiDepartment of Research and Development, Wecare Probiotics Co., Ltd., Suzhou, China.
Shuguang FangDepartment of Research and Development, Wecare Probiotics Co., Ltd., Suzhou, China.
Ying WuCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang, China.
Shaobin GuCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Probiotics have demonstrated potential application value in alleviating allergic diseases, but their mechanisms of action remain to be explored. This study aimed to investigate the clinical efficacy of probiotics in patients with allergic rhinitis (AR) and explore the underlying mechanisms. Methods: We evaluated the clinical intervention efficacy of Results: The results indicated that BC99 significantly alleviated nasal symptoms and improved quality of life, as evidenced by reduced TNSS and RQLQ scores (p < 0.05) and increased RCAT scores (p < 0.01). Furthermore, BC99 supplementation significantly decreased serum IgA, complement C3, EOS, and MDA levels (p < 0.05) while enhancing antioxidant capacity (increased GSH, stabilized SOD). Metabolomic analysis revealed that BC99 intervention induced 397 differential metabolite changes (136 upregulated, 261 downregulated) and significantly modulated AR-related metabolic pathways, including biosynthesis of unsaturated fatty acids, phenylalanine metabolism, and arginine biosynthesis (p < 0.05). Conclusion: This study confirms the efficacy of Clinical trial registration: https://clinicaltrials.gov, identifier NCT06680102.

Indexed as

Metabolic Networks and PathwaysOxidative StressProbioticsRhinitis, AllergicAdultBiomarkersDouble-Blind MethodFemaleHumansMaleMiddle AgedQuality of LifeTreatment OutcomeYoung AdultBiomarkersallergic rhinitisimmune factorsoxidative stressserum metabolismWeizmannia coagulans BC99

Identifiers

PMID41208993
PMCPMC12592054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.